Literature DB >> 30444932

Resurrection and Reactivation of Acetylcholinesterase and Butyrylcholinesterase.

Andrew J Franjesevic1, Sydney B Sillart1, Jeremy M Beck1, Shubham Vyas1,2, Christopher S Callam1, Christopher M Hadad1.   

Abstract

Organophosphorus (OP) nerve agents and pesticides present significant threats to civilian and military populations. OP compounds include the nefarious G and V chemical nerve agents, but more commonly, civilians are exposed to less toxic OP pesticides, resulting in the same negative toxicological effects and thousands of deaths on an annual basis. After decades of research, no new therapeutics have been realized since the mid-1900s. Upon phosphylation of the catalytic serine residue, a process known as inhibition, there is an accumulation of acetylcholine (ACh) in the brain synapses and neuromuscular junctions, leading to a cholinergic crisis and eventually death. Oxime nucleophiles can reactivate select OP-inhibited acetylcholinesterase (AChE). Yet, the fields of reactivation of AChE and butyrylcholinesterase encounter additional challenges as broad-spectrum reactivation of either enzyme is difficult. Additional problems include the ability to cross the blood brain barrier (BBB) and to provide therapy in the central nervous system. Yet another complication arises in a competitive reaction, known as aging, whereby OP-inhibited AChE is converted to an inactive form, which until very recently, had been impossible to reverse to an active, functional form. Evaluations of uncharged oximes and other neutral nucleophiles have been made. Non-oxime reactivators, such as aromatic general bases and Mannich bases, have been developed. The issue of aging, which generates an anionic phosphylated serine residue, has been historically recalcitrant to recovery by any therapeutic approach-that is, until earlier this year. Mannich bases not only serve as reactivators of OP-inhibited AChE, but this class of compounds can also recover activity from the aged form of AChE, a process referred to as resurrection. This review covers the modern efforts to address all of these issues and notes the complexities of therapeutic development along these different lines of research.
© 2019 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  acetylcholinesterase; butyrylcholinesterase; organophosphorus; reactivation; resurrection

Mesh:

Substances:

Year:  2019        PMID: 30444932      PMCID: PMC6508893          DOI: 10.1002/chem.201805075

Source DB:  PubMed          Journal:  Chemistry        ISSN: 0947-6539            Impact factor:   5.236


  122 in total

1.  A modular treatment of molecular traffic through the active site of cholinesterase.

Authors:  S A Botti; C E Felder; S Lifson; J L Sussman; I Silman
Journal:  Biophys J       Date:  1999-11       Impact factor: 4.033

2.  Analysis of a 10-ns molecular dynamics simulation of mouse acetylcholinesterase.

Authors:  K Tai; T Shen; U Börjesson; M Philippopoulos; J A McCammon
Journal:  Biophys J       Date:  2001-08       Impact factor: 4.033

3.  Abundant tissue butyrylcholinesterase and its possible function in the acetylcholinesterase knockout mouse.

Authors:  B Li; J A Stribley; A Ticu; W Xie; L M Schopfer; P Hammond; S Brimijoin; S H Hinrichs; O Lockridge
Journal:  J Neurochem       Date:  2000-09       Impact factor: 5.372

4.  Trapping phosphodiester-quinone methide adducts through in situ lactonization.

Authors:  Q Zhou; K D Turnbull
Journal:  J Org Chem       Date:  2000-04-07       Impact factor: 4.354

Review 5.  Selective inhibitors of butyrylcholinesterase: a valid alternative for therapy of Alzheimer's disease?

Authors:  E Giacobini
Journal:  Drugs Aging       Date:  2001       Impact factor: 3.923

6.  Does "butyrylization" of acetylcholinesterase through substitution of the six divergent aromatic amino acids in the active center gorge generate an enzyme mimic of butyrylcholinesterase?

Authors:  D Kaplan; A Ordentlich; D Barak; N Ariel; C Kronman; B Velan; A Shafferman
Journal:  Biochemistry       Date:  2001-06-26       Impact factor: 3.162

7.  Quinone methide phosphodiester alkylations under aqueous conditions.

Authors:  Q Zhou; K D Turnbull
Journal:  J Org Chem       Date:  2001-10-19       Impact factor: 4.354

8.  Phosphoryl oxime inhibition of acetylcholinesterase during oxime reactivation is prevented by edrophonium.

Authors:  C Luo; A Saxena; M Smith; G Garcia; Z Radić; P Taylor; B P Doctor
Journal:  Biochemistry       Date:  1999-08-03       Impact factor: 3.162

9.  Exploring the active center of human acetylcholinesterase with stereomers of an organophosphorus inhibitor with two chiral centers.

Authors:  A Ordentlich; D Barak; C Kronman; H P Benschop; L P De Jong; N Ariel; R Barak; Y Segall; B Velan; A Shafferman
Journal:  Biochemistry       Date:  1999-03-09       Impact factor: 3.162

10.  Phosphodiester Alkylation with a Quinone Methide.

Authors:  Qibing Zhou; Kenneth D. Turnbull
Journal:  J Org Chem       Date:  1999-04-16       Impact factor: 4.354

View more
  13 in total

1.  Positron emission tomography evaluation of oxime countermeasures in live rats using the tracer O-(2-[18 F]fluoroethyl)-O-(p-nitrophenyl)methylphosphonate [18 F]-VXS.

Authors:  Thomas R Hayes; Joseph E Blecha; Chih-Kai Chao; Tony L Huynh; Henry F VanBrocklin; Kurt R Zinn; Palmer W Taylor; John M Gerdes; Charles M Thompson
Journal:  Ann N Y Acad Sci       Date:  2020-05-20       Impact factor: 5.691

2.  Dual acting oximes designed for therapeutic decontamination of reactive organophosphates via catalytic inactivation and acetylcholinesterase reactivation.

Authors:  Jayme Cannon; Shengzhuang Tang; Kelly Yang; Racquel Harrison; Seok Ki Choi
Journal:  RSC Med Chem       Date:  2021-08-04

3.  Neuropathy target esterase (NTE/PNPLA6) and organophosphorus compound-induced delayed neurotoxicity (OPIDN).

Authors:  Rudy J Richardson; John K Fink; Paul Glynn; Robert B Hufnagel; Galina F Makhaeva; Sanjeeva J Wijeyesakere
Journal:  Adv Neurotoxicol       Date:  2020-03-03

4.  Ensemble machine learning to evaluate the in vivo acute oral toxicity and in vitro human acetylcholinesterase inhibitory activity of organophosphates.

Authors:  Liangliang Wang; Junjie Ding; Peichang Shi; Li Fu; Li Pan; Jiahao Tian; Dongsheng Cao; Hui Jiang; Xiaoqin Ding
Journal:  Arch Toxicol       Date:  2021-05-01       Impact factor: 5.153

Review 5.  Oximes: Novel Therapeutics with Anticancer and Anti-Inflammatory Potential.

Authors:  Igor A Schepetkin; Mark B Plotnikov; Andrei I Khlebnikov; Tatiana M Plotnikova; Mark T Quinn
Journal:  Biomolecules       Date:  2021-05-22

6.  Screening for Efficacious Anticonvulsants and Neuroprotectants in Delayed Treatment Models of Organophosphate-induced Status Epilepticus.

Authors:  Bryan S Barker; Jay Spampanato; Hilary S McCarren; Melissa Smolik; Cecelia E Jackson; Eden N Hornung; David T Yeung; F Edward Dudek; John H McDonough
Journal:  Neuroscience       Date:  2019-11-26       Impact factor: 3.708

Review 7.  Molecular Recognition of Nerve Agents and Their Organophosphorus Surrogates: Toward Supramolecular Scavengers and Catalysts.

Authors:  Tyler J Finnegan; Vageesha W Liyana Gunawardana; Jovica D Badjić
Journal:  Chemistry       Date:  2021-08-10       Impact factor: 5.020

Review 8.  Trends in the Recent Patent Literature on Cholinesterase Reactivators (2016-2019).

Authors:  Alexandre A de Castro; Letícia C Assis; Flávia V Soares; Kamil Kuca; Daniel A Polisel; Elaine F F da Cunha; Teodorico C Ramalho
Journal:  Biomolecules       Date:  2020-03-12

Review 9.  Enzymatic Bioremediation of Organophosphate Compounds-Progress and Remaining Challenges.

Authors:  Meghna Thakur; Igor L Medintz; Scott A Walper
Journal:  Front Bioeng Biotechnol       Date:  2019-11-08

Review 10.  Acetylcholinesterase: The "Hub" for Neurodegenerative Diseases and Chemical Weapons Convention.

Authors:  Samir F de A Cavalcante; Alessandro B C Simas; Marcos C Barcellos; Victor G M de Oliveira; Roberto B Sousa; Paulo A de M Cabral; Kamil Kuča; Tanos C C França
Journal:  Biomolecules       Date:  2020-03-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.